Yabao Pharmaceutical Group Co Ltd Total Assets
Yabao Pharmaceutical Group Co Ltd total assets. Based on the latest financial reports, Yabao Pharmaceutical Group Co Ltd (600351) holds total assets worth CN¥3.34 Billion CNY (≈ $489.15 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Yabao Pharmaceutical Group Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Yabao Pharmaceutical Group Co Ltd (1999–2024)
Total assets of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024. This chart illustrates how Yabao Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. See 600351 share price today for real-time trading data and today's change.
Yabao Pharmaceutical Group Co Ltd - Asset Composition Analysis
Yabao Pharmaceutical Group Co Ltd Total Assets Breakdown (December 2024)
Yabao Pharmaceutical Group Co Ltd total assets breakdown as of December 2024. Yabao Pharmaceutical Group Co Ltd's total assets of CN¥3.34 Billion consist of 44.0% current assets and 56.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.3% |
| Accounts Receivable | CN¥479.51 Million | 13.5% |
| Inventory | CN¥413.05 Million | 11.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥280.86 Million | 7.9% |
| Goodwill | CN¥26.27 Million | 0.7% |
Asset Composition Trend (1999–2024)
This chart illustrates how Yabao Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 600351 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yabao Pharmaceutical Group Co Ltd's current assets represent 44.0% of total assets in 2024, a decrease from 67.5% in 1999.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2024, up from 9.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 13.5% of total assets.
Yabao Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Yabao Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs96.12 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
China | CN¥3.61 Billion |
Yabao Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 2.60 | 1.57 |
| Quick Ratio | 2.49 | 2.04 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.01 Billion | CN¥1.02 Billion | CN¥625.03 Million |
Yabao Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Yabao Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.64 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -8.0% |
| Total Assets | CN¥3.54 Billion |
| Market Capitalization | $693.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yabao Pharmaceutical Group Co Ltd's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Yabao Pharmaceutical Group Co Ltd's assets decreased by 8.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Yabao Pharmaceutical Group Co Ltd (1999–2024)
The table below shows the annual total assets of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.54 Billion ≈ $518.59 Million |
-8.04% |
| 2023-12-31 | CN¥3.85 Billion ≈ $563.91 Million |
-6.72% |
| 2022-12-31 | CN¥4.13 Billion ≈ $604.51 Million |
+1.33% |
| 2021-12-31 | CN¥4.08 Billion ≈ $596.55 Million |
+1.55% |
| 2020-12-31 | CN¥4.01 Billion ≈ $587.42 Million |
-6.92% |
| 2019-12-31 | CN¥4.31 Billion ≈ $631.07 Million |
-10.64% |
| 2018-12-31 | CN¥4.83 Billion ≈ $706.23 Million |
+10.48% |
| 2017-12-31 | CN¥4.37 Billion ≈ $639.26 Million |
+3.88% |
| 2016-12-31 | CN¥4.21 Billion ≈ $615.40 Million |
-1.09% |
| 2015-12-31 | CN¥4.25 Billion ≈ $622.18 Million |
+33.50% |
| 2014-12-31 | CN¥3.18 Billion ≈ $466.07 Million |
-0.54% |
| 2013-12-31 | CN¥3.20 Billion ≈ $468.60 Million |
+11.02% |
| 2012-12-31 | CN¥2.88 Billion ≈ $422.08 Million |
+27.05% |
| 2011-12-31 | CN¥2.27 Billion ≈ $332.22 Million |
-6.62% |
| 2010-12-31 | CN¥2.43 Billion ≈ $355.76 Million |
+9.99% |
| 2009-12-31 | CN¥2.21 Billion ≈ $323.45 Million |
+32.02% |
| 2008-12-31 | CN¥1.67 Billion ≈ $245.00 Million |
+55.84% |
| 2007-12-31 | CN¥1.07 Billion ≈ $157.21 Million |
+6.34% |
| 2006-12-31 | CN¥1.01 Billion ≈ $147.83 Million |
-10.97% |
| 2005-12-31 | CN¥1.13 Billion ≈ $166.06 Million |
+21.00% |
| 2004-12-31 | CN¥937.81 Million ≈ $137.23 Million |
+41.04% |
| 2003-12-31 | CN¥664.93 Million ≈ $97.30 Million |
+48.63% |
| 2002-12-31 | CN¥447.38 Million ≈ $65.47 Million |
+71.13% |
| 2001-12-31 | CN¥261.43 Million ≈ $38.26 Million |
+18.26% |
| 2000-12-31 | CN¥221.07 Million ≈ $32.35 Million |
+14.30% |
| 1999-12-31 | CN¥193.41 Million ≈ $28.30 Million |
-- |
About Yabao Pharmaceutical Group Co Ltd
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 a… Read more